Skip to main content

Advertisement

Log in

Antigen receptor therapy in bone metastasis via optimal control for different human life stages

  • Published:
Journal of Mathematical Biology Aims and scope Submit manuscript

Abstract

In this work we propose a bone metastasis model using power law growth functions in order to describe the biochemical interactions between bone cells and cancer cells. Experimental studies indicate that bone remodeling cycles are different for human life stages: childhood, young adulthood, and adulthood. In order to include such differences in our study, we estimate the model parameter values for each human life stage via bifurcation analysis. Results reveal an intrinsic relationship between the active period of remodeling cycles and the proliferation of cancer cells. Subsequently, using optimal control theory we analyze a possible antigen receptor therapy as a new treatment for bone metastasis. Theoretical results such as existence of optimal solutions are proved. Numerical simulations for late stages of bone metastasis are presented and a discussion of our results is carried out.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9
Fig. 10

Similar content being viewed by others

Notes

  1. The vicious cycle comprises metastasis-derived signals that stimulate bone lining osteoblasts to proliferate and/or differentiate. In response to signals derived from the metastases, the bone lining osteoblasts express osteoclastogenic factors such as RANKL, which in turn, promotes the maturation of those precursors into active osteoclasts. Since bone is rich in growth factors (TGF\(-\beta \)), resorption by the osteoclasts results in the increased bioavailability of TGF\(-\beta \). Taken together, these osteoclast-generated factors facilitate the growth and expansion of the metastases thus completing the vicious cycle (Lynch 2011).

References

  • Ahmed N, Brawley VS, Hegde M, Robertson C, Ghazi A, Gerken C, Liu E, Dakhova O, Ashoori A, Corder A et al (2015) Human epidermal growth factor receptor 2 (her2)-specific chimeric antigen receptor-modified t cells for the immunotherapy of her2-positive sarcoma. J Clin Oncol 33(15):1688

    Article  Google Scholar 

  • Araujo A, Cook LM, Lynch CC, Basanta D (2014) An integrated computational model of the bone microenvironment in bone-metastatic prostate cancer. Can Res 74(9):2391–2401

    Article  Google Scholar 

  • Ayati B, Edwards C, Webb G, Wikswo J (2010) A mathematical model of bone remodeling dynamics for normal bone cell populations and myeloma bone disease. Biol Direct 5(1):28

    Article  Google Scholar 

  • Bayliss L, Mahoney D, Monk P (2012) Normal bone physiology, remodelling and its hormonal regulation. Surgery (Oxford) 30(2):47–53

    Article  Google Scholar 

  • Bilezikian JP, Raisz LG, Martin TJ (2008) Principles of bone biology. Academic Press, New York

    Google Scholar 

  • Bonifant CL, Jackson HJ, Brentjens RJ, Curran KJ (2016) Toxicity and management in car t-cell therapy. Mol Therapy-Oncolyt 3(16):011

    Google Scholar 

  • Business Wire (2021) U.S. Food and Drug Administration approves Bristol Myers Squibb’s and Bluebird Bio’s Abecma (idecabtagene vicleucel), the first anti-Bcma car T cell therapy for relapsed or refractory multiple myeloma. https://www.businesswire.com/news/home/20210326005507/en/. Accessed 20 May 2021

  • Camacho A, Jerez S (2019) Bone metastasis treatment modeling via optimal control. J Math Biol 78(1–2):497–526

    Article  MathSciNet  MATH  Google Scholar 

  • Camacho D, Pienta K (2014) A multi-targeted approach to treating bone metastases. Cancer Metastasis Rev 33(2–3):545–553

    Article  Google Scholar 

  • Cartellieri M, Bachmann M, Feldmann A, Bippes C, Stamova S, Wehner R, Temme A, Schmitz M (2010) Chimeric antigen receptor-engineered t cells for immunotherapy of cancer. J Biomed Biotechnol 2010:956304

    Article  Google Scholar 

  • Cook L, Araujo A, Pow-Sang J, Budzevich M, Basanta D, Lynch C (2016) Predictive computational modeling to define effective treatment strategies for bone metastatic prostate cancer. Sci Rep 6(29):384

    Google Scholar 

  • Eladdadi A, Kim P, Mallet D (2014) Mathematical models of tumor-immune system dynamics, vol 107. Springer, Berlin

    Book  MATH  Google Scholar 

  • Eriksen EF (2010) Cellular mechanisms of bone remodeling. Rev Endocr Metab Dis 11(4):219–227

    Article  Google Scholar 

  • Farhat A, Jiang D, Cui D, Keller ET, Jackson TL (2017) An integrative model of prostate cancer interaction with the bone microenvironment. Math Biosci 294:1–14

    Article  MathSciNet  MATH  Google Scholar 

  • Fleming W, Rishel R (2012) Deterministic and stochastic optimal control, vol 1. Springer, Berlin

    MATH  Google Scholar 

  • Garzón-Alvarado DA (2012) A mathematical model for describing the metastasis of cancer in bone tissue. Comput Methods Biomech Biomed Eng 15(4):333–346

    Article  MathSciNet  Google Scholar 

  • Ghaderi S, Lie R, Moster D, Ruud E, Syse A, Wesenberg F, Bjørge T (2012) Cancer in childhood, adolescence, and young adults: a population-based study of changes in risk of cancer death during four decades in norway. Cancer Cause Control 23(8):1297–1305

    Article  Google Scholar 

  • Gilham DE, Debets R, Pule M, Hawkins RE, Abken H (2012) Car-t cells and solid tumors: tuning t cells to challenge an inveterate foe. Trends Mol Med 18(7):377–384

    Article  Google Scholar 

  • Gonzalez H, Hagerling C, Werb Z (2018) Roles of the immune system in cancer: from tumor initiation to metastatic progression. Genes Dev 32(19–20):1267–1284

    Article  Google Scholar 

  • He Q, Liu Z, Liu Z, Lai Y, Zhou X, Weng J (2019) Tcr-like antibodies in cancer immunotherapy. J Hematol Oncol 12(1):99

    Article  Google Scholar 

  • Heaney RP (2001) Methods in nutrition science: the bone remodeling transient: interpreting interventions involving bone-related nutrients. Nutr Rev 59(10):327–334

    Article  Google Scholar 

  • Hillerdal V, Essand M (2015) Chimeric antigen receptor-engineered t cells for the treatment of metastatic prostate cancer. BioDrugs 29(2):75–89

    Article  Google Scholar 

  • Jackson HJ, Rafiq S, Brentjens RJ (2016) Driving car t-cells forward. Nat Rev Clin Oncol 13(6):370

    Article  Google Scholar 

  • Jerez S, Camacho A (2018) Bone metastasis modeling based on the interactions between the BMU and tumor cells. J Comput Appl Math 330:866–876

    Article  MathSciNet  MATH  Google Scholar 

  • Jerez S, Chen B (2015) Stability analysis of a komarova type model for the interactions of osteoblast and osteoclast cells during bone remodeling. Math Biosci 264:29–37

    Article  MathSciNet  MATH  Google Scholar 

  • Jilka RL (2003) Biology of the basic multicellular unit and the pathophysiology of osteoporosis. J Comput Appl Math 41(3):182–185

    Google Scholar 

  • Jinnah AH, Zacks BC, Gwam CU, Kerr BA (2018) Emerging and established models of bone metastasis. Cancers 10(6):176

    Article  Google Scholar 

  • Juárez P, Guise T (2011) TGF-\(\beta \) in cancer and bone: implications for treatment of bone metastases. Bone 48(1):23–29

    Article  Google Scholar 

  • June CH, O’Connor RS, Kawalekar OU, Ghassemi S, Milone MC (2018) Car t cell immunotherapy for human cancer. Science 359(6382):1361–1365

  • Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, June CH (2011) T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 3(95):95ra73

    Article  Google Scholar 

  • Klebanoff C, Yamamoto T, Restifo N (2014) Immunotherapy: treatment of aggressive lymphomas with anti-cd19 car t cells. Nat Rev Clin Oncol 11(12):685–6

    Article  Google Scholar 

  • Koenders M, Saso R (2016) A mathematical model of cell equilibrium and joint cell formation in multiple myeloma. J Theor Biol 390:73–79

    Article  MathSciNet  MATH  Google Scholar 

  • Komarova S, Smith R, Dixon S, Sims S, Wahl L (2003) Mathematical model predicts a critical role for osteoclast autocrine regulation in the control of bone remodeling. Bone 33(2):206–215

    Article  Google Scholar 

  • Lemos J, Caiado D, Coelho R, Vinga S (2016) Optimal and receding horizon control of tumor growth in myeloma bone disease. Biomed Signal Proces 24:128–134

    Article  Google Scholar 

  • Lenhart S, Workman J (2007) Optimal control applied to biological models. Chapman and Hall/CRC, Cambridge

    Book  MATH  Google Scholar 

  • Lo CH, Baratchart E, Basanta D, Lynch CC (2021) Computational modeling reveals a key role for polarized myeloid cells in controlling osteoclast activity during bone injury repair. Sci Rep 11(1):1–14

    Article  Google Scholar 

  • Louis CU, Savoldo B, Dotti G, Pule M, Yvon E, Myers GD, Rossig C, Russell HV, Diouf O, Liu E et al (2011) Antitumor activity and long-term fate of chimeric antigen receptor-positive t cells in patients with neuroblastoma. Blood J Am Soc Hematol 118(23):6050–6056

    Google Scholar 

  • Lynch CC (2011) Matrix metalloproteinases as master regulators of the vicious cycle of bone metastasis. Bone 48(1):44–53

    Article  Google Scholar 

  • Ma L, Dichwalkar T, Chang JY, Cossette B, Garafola D, Zhang AQ, Fichter M, Wang C, Liang S, Silva M et al (2019) Enhanced car-t cell activity against solid tumors by vaccine boosting through the chimeric receptor. Science 365(6449):162–168

    Article  Google Scholar 

  • Manolagas SC (2000) Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev 21(2):115–137

    Google Scholar 

  • Mundy G (2002) Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2(8):584

    Article  Google Scholar 

  • Muñoz AI, Tello JI (2017) On a mathematical model of bone marrow metastatic niche. Math Biosci Eng 14(1):289

    Article  MathSciNet  MATH  Google Scholar 

  • National Cancer Institute (2021) T cell transfer therapy. https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/t-cell-transfer-therapy

  • Neilan RM, Lenhart S (2010) An introduction to optimal control with an application in disease modeling. In: Modeling paradigms and analysis of disease trasmission models, pp 67–81

  • Newick K, Moon E, Albelda S (2016) Chimeric antigen receptor t-cell therapy for solid tumors. Mol Ther Oncolyt 3(16):006

    Google Scholar 

  • Ottewell PD (2016) The role of osteoblasts in bone metastasis. J Bone Oncol 5(3):124–127

    Article  Google Scholar 

  • Paget S (1889) The distribution of secondary growths in cancer of the breast. Lancet 133:571–573

    Article  Google Scholar 

  • Parfitt AM (1994) Osteonal and hemi-osteonal remodeling: the spatial and temporal framework for signal traffic in adult human bone. J Cell Biochem 55(3):273–286

    Article  Google Scholar 

  • Porter DL, Levine BL, Kalos M, Bagg A, June CH (2011) Chimeric antigen receptor-modified t cells in chronic lymphoid leukemia. N Engl J Med 365:725–733

    Article  Google Scholar 

  • Randall R, Lewis V, Weber K (2016) Metastatic bone disease. An integrated approach to patient care. Springer, New York

    Book  Google Scholar 

  • Rhodes A, Hillen T (2019) A mathematical model for the immune-mediated theory of metastasis. J Theor Biol 482(109):999

    MathSciNet  MATH  Google Scholar 

  • Rhodes A, Hillen T (2020) Implications of immune-mediated metastatic growth on metastatic dormancy, blow-up, early detection, and treatment. J Math Biol 81(3):799–843

    Article  MathSciNet  MATH  Google Scholar 

  • Rosenberg S (2011) Cell transfer immunotherapy for metastatic solid cancer-what clinicians need to know. Nat Rev Clin Oncol 8(10):577

    Article  Google Scholar 

  • Ryser M, Komarova S, Nigam N (2010) The cellular dynamics of bone remodeling: a mathematical model. SIAM J Appl Math 70(6):1899–1921

    Article  MathSciNet  MATH  Google Scholar 

  • Sarkar RR, Gloude NJ, Schiff D, Murphy JD (2019) Cost-effectiveness of chimeric antigen receptor t-cell therapy in pediatric relapsed/refractory b-cell acute lymphoblastic leukemia. JNCI J Natl Cancer Inst 111(7):719–726

    Article  Google Scholar 

  • Savageau MA (1988) Introduction to S-systems and the underlying power-law formalism. Math Comput Model 11:546–551

    Article  MathSciNet  Google Scholar 

  • Sousa S, Clézardin P (2018) Bone-targeted therapies in cancer-induced bone disease. Calcif Tissue Int 102(2):227–250

    Article  Google Scholar 

  • US Food and Drug Administration (2021) Package insert—abecma. https://www.fda.gov/media/147055/download. Accessed 20 May 2021

  • Vera J, Balsa-Canto E, Wellstead P, Banga JR, Wolkenhauer O (2007) Power-law models of signal transduction pathways. Cell Signal 19(7):1531–1541

    Article  Google Scholar 

  • Voit E (1991) Canonical nonlinear modeling: S-systems approach to understanding complexity. Chapman & Hall, Cambridge

    MATH  Google Scholar 

  • Walsh JS (2015) Normal bone physiology, remodelling and its hormonal regulation. Surgery (Oxford) 33(1):1–6

    Article  Google Scholar 

  • Wang RA, Li QL, Li ZS, Zheng PJ, Zhang HZ, Huang XF, Chi SM, Yang AG, Cui R (2013) Apoptosis drives cancer cells proliferate and metastasize. J Cell Mol Med 17(1):205–211

    Article  Google Scholar 

  • Weiner M, Weiner SL, Simone JV (2003) Childhood Cancer Survivorship: Improving Care and Quality of Life. Institute of Medicine (US) and National Research Council (US) National Cancer Policy Board. National Academies Press (US)

  • Wiggers SL, Pedersen P (2018) Routh-hurwitz-liénard-chipart criteria. Structural stability and vibration. Springer, Cham, pp 133–140

    Chapter  MATH  Google Scholar 

  • Zhao L, Cao Y (2019) Engineered t cell therapy for cancer in the clinic. Front Immunol 10:2250

    Article  Google Scholar 

  • Zumsande M, Stiefs D, Siegmund S, Gross T (2011) General analysis of mathematical models for bone remodeling. Bone 48(4):910–917

    Article  Google Scholar 

  • Zysk A, DeNichilo MO, Panagopoulos V, Zinonos I, Liapis V, Hay S, Ingman W, Ponomarev V, Atkins G, Findlay D et al (2017) Adoptive transfer of ex vivo expanded v\(\gamma \)9v\(\delta \)2 t cells in combination with zoledronic acid inhibits cancer growth and limits osteolysis in a murine model of osteolytic breast cancer. Cancer Lett 386:141–150

    Article  Google Scholar 

Download references

Acknowledgements

This work was supported by Mexico CONACyT project CB2016-286437. A.K.M. was partially funded by an NCI PSON U01 CA244101. The authors thank Dr. Ryan Bishop for helpful discussions on the content of this article.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Silvia Jerez.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Appendices

Bifurcation analysis

Based on the oscillations frequency, we carried out a bifurcation analysis with the numerical software XPPAUT/AUTO to give parameter values in the childhood, young adults and adulthood. Recalling that the solution of system (1) exhibits limit cycles or stable/unstable oscillations when equation (2) is satisfied. For this analysis, we study the effect of varying the parameters \(g_{11}\) and \(g_{22}\) on osteoclast steady states (c) in the bone remodeling model.

Fig. 11
figure 11

a Stability diagram of the osteoclast, c equilibrium point as a function of \(g_{11}\). Red line is stable, and black line is unstable. Hopf bifurcation appears at \(g_{11}=1.1\) and \(g_{22}=0.001\). b Bifurcation diagram of the osteoclast, c equilibrium for system (1). Green dots represent stable limit cycle and blue circles represent unstable limit cycles (colour figure online)

First, the bifurcation parameter was \(g_{11}\) and the other parameters were taken as \(g_{22}=0.0001\), \(g_{21} =1\) and \(g_{12}=-0.3\). Figure 11 shows the stability diagram of the equilibrium point and the Hopf bifurcation varying \(g_{11}\). The structure of the bifurcation diagram for model (1) is illustrated in Fig. 11b. Using a two parameter variation we obtained that limit cycles occur when \(g_{11}\in [1.099\;\; 1.161048]\) and \(g_{22}\in [-0.6104841\;\; 0)\). Recall that negative real-valued for kinetic orders describe inhibition activity. For the second case, the bifurcation parameter was \(g_{22}\). The other parameters were: \(g_{11}=0.90\), \(g_{21} =1\) and \(g_{12}=-0.3\) (the smallest/largest allowable values for \(g_{21}\) and \(g_{12}\) are 0.2 and \(-0.1\) respectively, after that the system does not present oscillations).

Fig. 12
figure 12

Hopf bifurcation diagrams of the osteoclast (c) equilibrium point of model (1) as a function of \(g_{22}\). Red line is stable, and black line is unstable. Green dots represent stable limit cycle and blue circles represent unstable limit cycles. Hopf bifurcation occurs at values listed (colour figure online)

Figure 12 shows the diagram of the variation of the equilibrium point and the Hopf bifurcation. Notice that for values of \(g_{11}\) less than 0.90 the Hopf bifurcation was not found. Fig. 12a, b show some of the bifurcation dynamics: when parameter \( g_ {22}\) decreases then the stability region also decreases, and the instability region increases (see red and black lines). In such analysis, we obtained that limit cycles occur when \(g_{11}\in [0.90\;\; 1.161]\) and \(g_{22}\in [-0.61\;\; 2.0]\), with \(g_{12}\in [-1.0\;\; -0.1]\) and \(g_{21}\in [0.2\;\; 1.0]\). We also analyzed the oscillations frequency for parameter values close to the bifurcation, which allowed us to classify them in three stage: (a) If \(g_{12}\in [-0.3\;\; -0.1]\) the BMU is less active, that is BMU has long periods of inactivity (adulthood stage); (b) if \(g_{12}\in [-0.7\; \; -0.3)\) the BMU is more active, that is, the period of activity is approximately of 6 months (young adult stage), (c) finally if \(g_{12}\in [-1.0\; -0.7)\) the BMU is more active and does not have inactive periods, that is, BMU is constantly remodeling (childhood stage). Therefore, with all the previous information we were able to classify the BMU behavior for three different stages in Table 1.

Proof of Theorem 3

The existence of optimal solutions for control problem (9)–(12) is obtained if the sufficient conditions of the Filippov-Cesari theorem (Fleming and Rishel 2012) are fulfilled:

(i):

The right-hand side of the model (10) is composed of continuous functions, and for each one of these functions \(f_{i}\) there exist positive constant \({\mathcal {C}}_{1}\), \({\mathcal {C}}_{2}\) such that \(\mid f_{i}(t,x,u)\mid \le {\mathcal {C}}_{1}(1+\mid x\mid +\mid u\mid )\) and \(\mid f_{i}(t,{\overline{x}},u)-f_{i}(t,x,u)\mid \le {\mathcal {C}}_{2}\mid {\overline{x}}-x\mid (1+\mid u\mid )\) for all \(0\le t\le t_{f}\) and \(i=1,2,3\) and \(x(t)=(C(t),B(t),T(t))\).

(ii):

A solution of the dynamical system (10) is well defined and is unique for an admissible \(u\in \varGamma \).

(iii):

The set of solutions to system (10) is non-empty and bounded for admissible control functions \(u\in \varGamma \).

(iv):

The control set \(\varGamma \) is closed, bounded and convex in \(\mathrm{I\!R}\).

(v):

The right-hand side of the dynamical system (10) is linear in control u.

(vi):

The integrand of function (9) is convex with respect to u and satisfies

$$\begin{aligned} T(t)+\frac{B}{2}u^{2}(t)\ge {\mathcal {K}}_{1}\mid u\mid ^{\theta }-{\mathcal {K}}_{2}, \end{aligned}$$

with constants \({\mathcal {K}}_{1}>0\), \(\theta >1\) and \({\mathcal {K}}_{2}\).

Item (i) holds since the model functions are of class \(C^2\) in \(\varOmega \). Item (ii) holds since the admissible control set \(\varGamma \) contains continuous bounded functions and the right-hand side of (10) is Lipschitz continuous with respect to the three variables C, B and T for admissible \(u(t)\in \varGamma \). Using Picard-Lindelöf theorem, there exists a unique solution \((C(t), B(T), T(t))\in \varOmega \) corresponding to the admissible control \(u(t):\mathrm{I\!R}^{+}\mapsto [0,u_{c}]\). When the control variable takes its minimum value, that is, \(u(t)=0\) in (10), we recover the initial model without control (4) whose orbits C(t), B(t) and T(t) of \((C(0),B(0), T(0))\in \varOmega \) are bounded for all \(t\ge 0\). Therefore, solutions of the system (10) with \(u(t)=0\) can be regarded as its super-solution. On the other hand, when the control variable is at the upper bound, that is, \(u(t)=u_{c}\), the underlying solution of the system (10) can be regarded as its sub-solutions. Moreover, applying the Carathéodory’s existence theorem guarantees the existence of solutions for Cauchy problems. The latter implies that item (iii) holds. Additionally, by the definition of the admissible control set \(\varGamma \) in (12) is clear that this set control is closed, bounded and convex in \(\mathrm{I\!R}\). Thus, (iv) holds. To proof the item (v), let f(txu) be the vector function defined by right-hand side of (10), we will find suitable bounds for the states:

$$\begin{aligned} \frac{dC(t)}{dt}= & {} \alpha _{1}C(t)B(t)^{g_{12}} -\beta _{1}C(t)+ (\sigma _{1}-a_{1}u(t))C(t)T(t)\nonumber \\\le & {} C(t)(\alpha _{1}m_{1} + \sigma _{1}C_{max})\; \; (g_{12}<0\;\;and\;\; m_{1}:=(B_{min})^{g_{12}}). \end{aligned}$$
(18)

On the other hand,

$$\begin{aligned} \frac{dB(t)}{dt}= & {} \alpha _{2}C(t)^{g_{21}}B(t)-\beta _{2}B(t)+(\sigma _{2}-a_{2}u(t))B(t)T(t),\nonumber \\\le & {} \left\{ \begin{array}{lcc} B(t)(\alpha _{2}m_{2} + \sigma _{2}C_{max})&{}&{} if\;\; \sigma _{2}\ge 0, \\ B(t)\alpha _{2}m_{2} &{}&{}if\;\;\sigma _{2}<0, \end{array} \right. \end{aligned}$$
(19)

where \(m_{2}:=(C_{max})^{g_{21}}\). Finally,

$$\begin{aligned} \frac{dT(t)}{dt}= & {} \alpha _{3}C(t)^{g_{31}}T(t)\left( 1-\frac{T(t)}{K}\right) -(\beta _{3}+u(t))T(t)\nonumber \\\le & {} T(t)(\alpha _{3}m_{2} -\beta _{3}). \end{aligned}$$
(20)

Thus, from (18)–(20) we have that our model is bounded by a linear system. Item vi), the integrand of (9) is quadratic in u, and therefore convex. Condition \(T(t)+\frac{B}{2}u^{2}(t)\ge {\mathcal {K}}_{1}\mid u\mid ^{\theta }-{\mathcal {K}}_{2}\) is fulfilled with \({\mathcal {K}}_{2}=0\), \(\theta =2>1\) and \({\mathcal {K}}_{1}=\frac{B}{2}>0\).

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Jerez, S., Pliego, E., Solis, F.J. et al. Antigen receptor therapy in bone metastasis via optimal control for different human life stages. J. Math. Biol. 83, 44 (2021). https://doi.org/10.1007/s00285-021-01673-4

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s00285-021-01673-4

Keywords

Mathematics Subject Classification

Navigation